VC: NovImmune garners $46M in second round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

NovImmune
Switzerland

$46M
Second

BZ Bank and Private Equity Investors

NovImmune will use the funds to advance further products from its pipeline of fully human antibodies into clinical development.

VaxInnate
Cranbury, NJ

$40M
Third

Leaf Venture Partners and Canaan Partners

VaxInnate is developing new flu vaccines.

Esperance Pharmaceuticals
Baton Rouge, LA

$9M
First

Themelios Ventures Partners and Research Corporation Technologies

Esperance is developing a targeted anticancer fusion protein that is selectively toxic to cancer cells.